Loading…
LEMOCALM PLUS COLD AND FLU is a brand name for Phenylephrine. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: Symptomatic relief of symptoms of influenza, feverishness, chills and colds including feverish colds. The symptomatic relief of nasal congestion and difficult breathing arising from this, sinusitis and its associated pain, acute nasal catarrh
Verbatim from this product's MHRA label. Tap a section to expand.
Posology:
Adults (including elderly) and children aged 16 years and over: Two capsules every 4 - 6 hours as required. 12 capsules in any 24 hours. Do not take continuously for more than 7 days without medical advice. Do not exceed the stated dose.
Use the lowest amount needed to achieve benefit for the shortest duration of treatment.
Children aged 12 years to 15 years:
Two capsules every 4 - 6 hours when necessary to a maximum of 4 doses in 24 hours. Do not exceed 8 capsules in any 24 hours.
Children under 12 years of age:
LemoCalm Plus Cold and Flu Capsules are not recommended for children under the age 12.
Method of administration:
For oral administration
Adverse events of paracetamol from historical clinical trial data are both infrequent and from small patient exposure. Accordingly, events reported from extensive post- marketing experience at therapeutic/labelled dose and considered attributable are tabulated below by system class.
The frequency of these adverse events is not known (cannot be estimated from available data). (i) Paracetamol System Undesirable effect Blood and lymphatic system disorders Thrombocytopenia Agranulocytosis These are not necessarily causally related to paracetamol.
Immune system disorders Anaphylaxis Cutaneous hypersensitivity reactions including skin rashes, angioedema Very rare cases of serious skin reactions have been reported. Respiratory, thoracic and mediastinal disorders Bronchospasm* Hepato-biliary disorders Hepatic dysfunction Metabolism and nutrition disorders High anion gap metabolic acidosis * There have been cases of bronchospasm with paracetamol, but these are more likely in asthmatics sensitive to aspirin or other NSAIDs.
4). Pyroglutamic acidosis may occur as a consequence of low glutathione levels in these patients. (ii) Caffeine Adverse reactions identified through post-marketing use with caffeine are listed below. The frequency of these reactions is unknown.
Central Nervous system Excitability Dizziness and headache Psychiatric disorders Nervousness, insomnia, restlessness, anxiety and irritability Cardiac disorders Palpitations Gastrointestinal disorders Gastrointestinal disturbances When the recommended paracetamol-caffeine dosing regimen is combined with dietary caffeine intake, the resulting higher dose of caffeine may increase the potential for caffeine-related adverse effects.
(iii) Phenylephrine hydrochloride The following adverse events have been observed in clinical trials with phenylephrine and may therefore represent the most commonly occurring adverse events. Body system Undesirable effect Psychiatric disorders Nervousness Nervous system disorders headache, dizziness, insomnia Cardiac disorders Increases in blood pressure Gastrointestinal disorders nausea, vomiting, diarrhoea Adverse reactions identified during post-marketing use are listed below.
Contains paracetamol. Patients should be advised not to take other paracetamol- containing products concurrently. The concomitant use with other products containing paracetamol may lead to an overdose. Paracetamol overdose may cause liver failure which may require liver transplant or lead to death.
Concomitant use of other decongestants or cold and flu medicines should be avoided. g. chronic alcoholism) who were treated with paracetamol at therapeutic dose for a prolonged period or a combination of paracetamol and flucloxacillin.
If HAGMA due to pyroglutamic acidosis is suspected, prompt discontinuation of paracetamol and close monitoring is recommended. The measurement of urinary 5-oxoproline may be useful to identify pyroglutamic acidosis as underlying cause of HAGMA in patients with multiple risk factors.
The hazard of overdose is greater in those with non-cirrhotic alcoholic liver disease. Underlying liver disease increases the risk of paracetamol-related liver damage. Medical advice should be sought before using this product in patients with these conditions: • Medical advice should be sought before taking this medicine in patients with: glutathione depletion due to metabolic deficiencies.
g. Raynaud's phenomenon); • Cardiovascular disease. This product should not be used by patients taking other sympathomimetics (such as decongestants, appetite suppressants and amphetamine-like psychostimulants) (see interactions). g. coffee, tea and some canned drinks) should be avoided while taking this product.
Keep out of the sight and reach of children. Do not exceed the stated dose If symptoms persist consult your doctor If you are under the care of your doctor or receiving prescribed medicines consult your doctor before taking this product.
Special Label Warnings Contains paracetamol. Do not take anything else containing paracetamol while taking this medicine. Do not take with other flu, cold or decongestant products. Do not take more medicine than the label tells you to.
5).
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Phenylephrine in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
The frequency of these reactions is unknown. Immune system disorders Hypersensitivity, allergic dermatitis, urticaria Eye disorders Mydriasis, acute angle closure glaucoma, most likely to occur in those with closed angle glaucoma. Cardiac disorders Tachycardia, palpitations.
Skin and subcutaneous disorders Rash, Renal and urinary disorders Dysuria, urinary retention. This is most likely to occur in those with bladder outlet obstruction, such as prostatic hypertrophy. Reporting of Suspected Adverse Reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
If you do not get better, talk to your doctor. Talk to a doctor at once if you take too much of this medicine, even if you feel well. Special Leaflet Warnings Talk to a doctor at once if you take too much of this medicine even if you feel well.
This is because too much paracetamol can cause delayed, serious liver damage
+3 more